Jazz Pharmaceuticals plc Form 5 Feb F

February 11,	2016											
FORM 5								OMB A	OMB APPROVAL			
UNITED STATES SECURITIES AND EXCHANGE COMMISSIO Check this box if Washington, D.C. 20549						OMMISSION	Number.	3235-0362 January 31,				
no longer to Section Form 4 or 5 obligatic may contin <i>See</i> Instruc 1(b).	16. ANI Form ANI ons nue. ction	ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 193							Expires: 2005 Estimated average burden hours per response 1.0			
Form 3 Holdings Section 17(a) of the Public Utility Holding Company Act of 1935 or Section Reported Form 4 30(h) of the Investment Company Act of 1940 Transactions Reported												
1. Name and Address of Reporting Person <u>*</u> Hooper Suzanne Sawochka			2. Issuer Name and Ticker or Trading Symbol Jazz Pharmaceuticals plc [JAZZ]					5. Relationship of Reporting Person(s) to Issuer				
(Last)	(First)		3. Statement for Issuer's Fiscal Year Ended (Month/Day/Year) 12/31/2015				(Check all applicable) Director 10% Owner X Officer (give title Other (specify					
CONNAUGHT HOUSE, 1 BURLINGTON RD, FL. 4					below) below) EVP & General Counsel							
	(Street) 4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Reporting (check applicable line)					
DUBLIN 4,	L2Â							_X_ Form Filed by Form Filed by M Person	One Reporting P More than One R			
(City)	(State)	(Zip)	Tabl	e I - Non-Deri	vative Se	curities	s Acqu	iired, Disposed of	f, or Beneficial	ly Owned		
1.Title of Security (Instr. 3)	2. Transaction Da (Month/Day/Year		n Date, if	3. Transaction Code (Instr. 8)		d (A) or d of (D) , 4 and 5 (A) or)	Securities Beneficially	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)			
Ordinary Shares	12/07/2015	Â		G	260	D	\$0	35,647 <u>(1)</u>	D	Â		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information SEC 2270 contained in this form are not required to respond unless (9-02)the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	Expiration D (Month/Day/	Expiration Date (Month/Day/Year)		le and unt of rlying ities . 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. of D S G E I S Fi (I
					(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Edgar Filing: Jazz Pharmaceuticals plc - Form 5

Reporting Owners

Reporting Owner Name / Address		Relationships					
1	Director	10% Owner	Officer	Other			
Hooper Suzanne Sawochka CONNAUGHT HOUSE, 1 BURLINGTON RD, FL. 4 DUBLIN 4, L2Â	Â	Â	EVP & General Counsel	Â			
Signatures							
By: /s/ Karen Eberle as attorney in fact For: Suzanne Sawo Hooper	chka	02/11/2016					
**Signature of Reporting Person		Date					
Explanation of Responses:							

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Includes 52 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on November 30, 2015.

Note: File three copies of this Form, one of which must be manually signed. If space provided is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.